1-2 of 2
Laure Devlamynck
Close
Sort by
Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal
Journal: Blood
Blood (2021) 138 (Supplement 1): 464.
https://doi.org/10.1182/blood-2021-146040
Published: 2021
Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3159.
https://doi.org/10.1182/blood-2019-123184
Published: 2019